摘要
背景与目的:MicroRNAs是一类19～25 bp内源非编码的小分子RNA,通过靶向抑制基因的转录和翻译水平。本文旨在探讨miR-222与甲基结合结构域蛋白2(methyl-CpG binding domain protein 2,MBD2)在结肠癌组织中的表达及其临床意义。方法:收集2008年1月—2010年6月结肠癌患者手术标本76例,癌旁组织作为正常对照,分别运用原位杂交、免疫组化检测结肠癌组织及癌旁组织中miR-222、MBD2的表达水平,分析其与结肠癌临床病理参数的关系。结果:原位杂交检测显示,在76例结肠癌组织中miR-222阳性表达率为92.1%,与癌旁对照组28.9%相比,差异有显著统计学意义(P<0.01);光密度值检测发现,miR-222的表达随着结肠癌临床分期的演进而增加,且结肠癌中有淋巴结转移的miR-222的表达显著高于无淋巴结转移组(P<0.01);免疫组化结果显示,在76例结肠癌组织中MBD2蛋白阳性表达率为19.7%,与癌旁对照组81.6%相比,差异有显著统计学意义(P<0.01);光密度值检测发现,MBD2的表达随着结肠癌临床分期的演进而下调,结肠癌中有淋巴结转移的MBD2的表达显著低于无淋巴结转移组(P<0.01);相关性分析表明,miR-222表达与MBD2的表达呈负相关(P<0.05)。结论:高表达的miR-222可通过靶向抑制MBD2的表达参与结肠癌的发生、发展、侵袭和转移,miR-222及MBD2可成为结肠癌治疗、预后判断的潜在生物学指标。
Background and purpose：MicroRNAs are 19 to 25-nucleotide noncoding RNA molecules that regulate gene expression at the level of transcription and translation.This study investigated the expression of the miR-222 and methyl-CpG binding domain protein 2（MBD2） in tissues of colon carcinoma and their clinical significance.Methods：Tissue specimens and adjacent tissues of 76 cases as control from Jan.2008 to Jun.2010 were collected,and hybridization in situ and immunohistochemistry were used to detect the miR-222 and MBD2 expression in those specimens respectively.Results：The positive expression rate of the miR-222 was 92.1% in colon carcinoma and 28.9% in adjacent comparison.The up-regulation of miR-222 expression was associated with advanced clinical stage,and the expression of miR-222 was higher with lymph node metastasis than without lymph node metastasis in colon carcinoma.The positive expression rate of the MBD2 was 19.7% in colon carcinoma and 81.6% in adjacent comparison.The down-regulation of MBD2 expression was associated with advanced clinical stage,and the expression of MBD2 was lower with lymph node metastasis than without lymph node metastasis in colon carcinoma.The expression of miR-222 had a close negative correlation to that of MBD2 in colon carcinoma（P0.01）.Conclusion：Overexpression of miR-222 might be associated with the tumorigenesis,development and metastasis by targeting MBD2,and they could be the indicators in the diagnosis and prognosis of colon carcinoma.
出处
《中国癌症杂志》
CAS
CSCD
北大核心
2012年第1期21-24,共4页
China Oncology
